BioNexus Gene Lab Corp - Common stock (BGLC)
Healthcare › Services-Medical Laboratories
Price History
Feb 9, 2026 — Aug 19, 2026Investment Snapshot
- P/B of 0.75 — trading below book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -27.7%
- Revenue declining 22% annually
BioNexus Gene Lab Corp - Common stock (BGLC) is a Healthcare company operating in Services-Medical Laboratories, listed on the NASDAQ , with a market capitalisation of $6 million . Key value metrics: P/B ratio 0.75, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
BioNexus Gene Lab Corp - Common stock — Fundamental Analysis Summary
On financial health, BGLC shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -27.7% (sector average: -20.1%), and minimal leverage with a debt-to-equity ratio of 0.12.
StockPik's composite Value Score for BGLC is 60/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BGLC reports a thin gross margin of 15.5% (sector average: 37.4%) and a negative operating margin of -43.6%.
BGLC shows revenue declining at 22% year-over-year, with earnings declining at 87%.